Nanna Lüneborg PhD, MBA
General Partner
MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders.
The company was founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients.
MapLight’s lead product candidate, ML-007C-MA, is an oral, extended-release, fixed-dose combination of an investigational M1/M4 muscarinic agonist, ML-007, co-formulated with a peripherally acting anticholinergic. ML-007C-MA is currently being evaluated in Phase 2 clinical trials for the treatment of schizophrenia and Alzheimer’s disease psychosis.
Industry
Biotech
Status
Current
Location
US
Maplight is pioneering innovative new therapies for patients suffering from brain disorders. Forbion has been a great partner to us in catalyzing one of the largest private financing rounds in 2025, together with an outstanding syndicate of private, public and strategic investors. This financing provides critical support for two significant Phase 2 studies of our lead molecule, ML-007, while continuing to advance the rest of MapLight's pipeline. We look forward to continuing our partnership with Forbion and our other shareholders to bring important medicines to patients with central nervous system disorders.Chris Kroeger
CEO of MapLight Therapeutics
$372.5m
Series D Oversubscribed
Forbion team
Regina Salvat PhD
Principal